Announcements Trials
Browse Landscape

Phase

Phase 3 18Phase 2 18Phase 2/3 7Phase 1 3Phase 1/2 2Phase NA 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Vulvar Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Specimen Handling 98Biopsy 69Magnetic Resonance Spectroscopy 63pembrolizumab 46Cyclophosphamide 43fludarabine 38Carboplatin 22venetoclax 19Nivolumab 18Cetuximab 18Bevacizumab 17Radiotherapy 16fludarabine phosphate 15Cisplatin 15X-Rays 14Ipilimumab 13Fluorouracil 13Cytarabine 13Temozolomide 12Leucovorin 12Irinotecan 12atezolizumab 11Radiation 11Paclitaxel 11Azacitidine 11durvalumab 10Oxaliplatin 10Injections 10Gemcitabine 10Dexamethasone 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Platinum × 30 days × Clear all
NCT04169763 2026-05-20

Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 1 Recruiting
25 enrolled
Gynecologic

Vulvar Neoplasms

NCT05172245 2026-05-18

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
46 enrolled
Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡